Nuevolution AB (publ) annual report 2016/17 now available

Stockholm, 18 September 2017. Nuevolution AB (publ) announces that its annual report 2016/17 now is available on the company’s home page (www.nuevolution.com).

 

For more information, please contact:

Alex Haahr Gouliaev, CEO
Phone: +45 3913 0902
Email: [email protected]

Henrik Damkjær Simonsen, CFO
Phone: +45 3913 0947
Email: [email protected]

 

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the Securities Market Act. The information was sent for publication on Monday 18 September at 8:45 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.